Skip to main content

Research Repository

Advanced Search

All Outputs (3)

Cytotoxicity and genotoxicity of electrochemically activated solutions (ECAS) (2017)
Journal Article
May, J., Robinson, G., Thorn, R., & Reynolds, D. (2017). Cytotoxicity and genotoxicity of electrochemically activated solutions (ECAS). Mutagenesis, 32(6), 622-623. https://doi.org/10.1093/mutage/gex033

Electrochemically activated solutions (ECAS) are of interest as potential disinfectants due to high biocidal activity against many microorganisms. They are widely used clinically in some countries (decontamination of surgical instruments and wounds),... Read More about Cytotoxicity and genotoxicity of electrochemically activated solutions (ECAS).

Development of a 2D leukaemia-stroma model for analyses of chemo-toxicity protection using a novel bacterial bioluminescent biosensor (2017)
Journal Article
Gynn, L., May, J., Anderson, E., & Robinson, G. (2017). Development of a 2D leukaemia-stroma model for analyses of chemo-toxicity protection using a novel bacterial bioluminescent biosensor. Mutagenesis, 32(6), 619. https://doi.org/10.1093/mutage/gex033

This study aimed to develop a 2D leukaemia-stroma model of the bone marrow for analysis of stromal-mediated chemo-protection; known to contribute to chemotherapy resistance. The model must facilitate integration of a bioluminescent biosensor HA1 for... Read More about Development of a 2D leukaemia-stroma model for analyses of chemo-toxicity protection using a novel bacterial bioluminescent biosensor.

Rapid in vitro testing and characterization of resistance to chemotherapeutic agents daunorubicin and cytarabine in acute myeloid leukaemia (2017)
Journal Article
May, J., Steven, J., Taylor, A., Dean, S., & Anderson, E. (2017). Rapid in vitro testing and characterization of resistance to chemotherapeutic agents daunorubicin and cytarabine in acute myeloid leukaemia. Mutagenesis, 32(6), 627. https://doi.org/10.1093/mutage/gex033

Treatment success in leukaemia is impacted by patient resistance to chemotherapy including cytarabine (ara-C) and the anthracycline daunorubicin (DNR) requiring rapid pre-screening testing. DNR is converted to daunorubicinol (DNRol) by carbonyl reduc... Read More about Rapid in vitro testing and characterization of resistance to chemotherapeutic agents daunorubicin and cytarabine in acute myeloid leukaemia.